Advanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue Guardant Health, Inc.

A head-to-head study pitting Guardant Health’s lung cancer blood test against standard, tissue-based testing found that the liquid biopsy was able to deliver similar results much faster and with more ...

MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, ...

Medscape: If your findings suggest that biopsy can contribute to the early identification of PD, what would be the clinical implications? Dr. Adler: To date, there is no tissue diagnostic test for PD, ...

Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health ...

Animal studies often fail to predict human tissue responses to new drugs or newly developed therapies. Besides generating ...

GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...